CuriMeta Launches in Collaboration with BJC HealthCare and Washington University in St. Louis to Empower Researchers With Advanced Real-World Health Data

CuriMeta, a life science-focused, real-world health data company, announced a collaboration with BJC HealthCare (BJC) and Washington University School of Medicine in St. Louis (WashU Medicine), who also led the $6 Million Series Seed Funding round.

The funding will allow CuriMeta to securely and privately transform, curate, and aggregate real-world health data from a major academic research organization and leading health system to provide researchers with indispensable insights and the evidence required to solve urgent scientific and clinical challenges and improve healthcare for all.

Driven by the belief that health system-sourced data can provide superior depth and insight into patient populations, CuriMeta’s medical data experts will analyze, expand, and organize the aggregated data into multiple, secure, privacy-protecting datasets that can be used by researchers to advance our understanding of health and disease and to develop lifesaving c****. By enabling and accelerating the exchange of advanced real-world health data with the research community, CuriMeta will enable life science organizations to accelerate their research and bring new diagnostics and interventions to patients and their care providers. CuriMeta’s goal is to accelerate the research aims of both academic and industry researchers and help to fulfill their missions of improving patient care and saving lives.

Recommended AI News: iWave Kicks off New Integration With Ascend by UC Innovation Built on Salesforce

CuriMeta will also deploy and utilize cutting-edge, privacy-protecting technologies that will allow data contributors, such as health systems, to know when and how the data they share via CuriMeta is being used. In addition, through the use of advanced computational methods, such as the generation of synthetic data using modern AI techniques, CuriMeta will ensure that patient confidentiality is maintained at a level that meets and exceeds current guidelines for the secure and private sharing of health data.

CuriMeta’s potential collaborators and partners include health systems and academic medical centers, life science manufacturers, and clinical research organizations, particularly those working in oncology, cardiology, and neurology. CuriMeta will be a vital conduit that will help connect leading, mission-driven health systems and academic medical centers with life-science organizations to pursue ground-breaking research and deliver new diagnostics and therapeutics faster than has been possible in the past.

“We are investing significantly in augmenting and improving the usefulness of the data, not just gathering it,” said Davis Walp, CuriMeta Founder and Chief Executive Officer. “Our data experts will curate, harmonize, and apply machine learning techniques to enhance the quality, completeness, and research value of our collaborators’ data. This is a team of mission focused industry veterans who understand the pressing scientific and clinical challenges that researchers are solving for. We’re aggregating and delivering advanced, real-world health data designed to answer those questions and address those needs.”

Recommended AI News: Leading Global Fintech Provider Selects Infobird Co., Ltd. to Deliver its Industry Leading Digital and Intelligent Customer Engagement Solution

With a commitment to full transparency, integrity, and accountability, CuriMeta will work closely with its collaborators to jointly review and approve all data requests from researchers, and will adhere to the most stringent data security, patient privacy, and compliance standards set forth by collaborating health systems, academic health centers, other data contributors, and regulatory authorities. To ensure patient privacy, all health data will be aggregated and de-identified or synthesized so that they provide privacy and confidentiality levels beyond currently required safeguards. In doing so, CuriMeta will advance both state-of-the-art real-world data research and privacy-protecting data sharing technologies.

“Increasingly complex therapies require deeper evidence and the demonstration of higher levels of clinical value and impact in order to receive acceptance and adoption by providers and patients, as well as regulatory approval—and it is becoming increasingly difficult for researchers to access the data necessary to prove such value,” said Darren Brodeur, CuriMeta’s Chief Commercial Officer and founding team member. “CuriMeta will help address this problem by providing the types of comprehensive, secure, and high-quality health data to researchers in order to ultimately prove the safety, efficacy, and clinical value of new or existing diagnostics and treatments.”

Recommended AI News: KPMG and Microsoft Collaborate to Help C-Suites Predict Tax Outcomes and Set Business Strategy With New Cloud Technologies

[To share your insights with us, please write to sghosh@martechseries.com]